Early Intensification with bendamustine supercharge plus brentuximab vedotinfollowing failure to obtain complete metabolic remission after two cycles of ABVD inpatients aged ≤60 years with classic Hodgkin lymphoma. Comment on:"Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkinlymphoma: the LYSA real-world experience&quo
